Q3 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: MXN454.55

Transcript 8-K10-Q

Key Points

Positve

Arrowhead Pharmaceuticals Inc (ARWR) has made significant progress in its late-stage clinical trials, with full enrollment achieved in several Phase 3 studies, indicating strong momentum in its drug development pipeline.
The company has a robust partnership with Sarepta Therapeutics, which continues to provide a source of capital and development support, ensuring the advancement of licensed programs.
Arrowhead Pharmaceuticals Inc (ARWR) has a strong balance sheet with cash and investments totaling $900.4 million as of June 30, 2025, providing financial stability and resources for future growth.
The company is on track to meet its '20 in 25' initiative, aiming to have 20 drug candidates in clinical studies or at market by the end of 2025, showcasing a broad and diverse pipeline.
Commercial preparations for the launch of posaceran are well underway, with a fully assembled sales team and strong engagement with healthcare professionals and payers, indicating readiness for market entry.

Negative

Arrowhead Pharmaceuticals Inc (ARWR) reported a net loss of $175.2 million for the quarter ended June 30, 2025, reflecting ongoing financial challenges.
The company's stock price has been negatively affected by setbacks experienced by its partner, Sarepta Therapeutics, in unrelated programs, highlighting potential volatility in its market valuation.
There is uncertainty regarding the pricing strategy for posaceran in the severe hypertriglyceridemia market, which could impact revenue projections.
The biotech market remains challenging, with broader market sentiments beyond the company's control, potentially affecting investor confidence and stock performance.
The company faces competition from other programs in the triglyceride reduction space, with uncertainties around the outcomes of competitor studies potentially impacting its market position.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ARWR.OQ - Arrowhead Pharmaceuticals Inc
Q3 2025 Arrowhead Pharmaceuticals Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference over to Vince Anzalone, Vice President of investor relations for Arrowhead. Please go ahead, Vince.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon, everyone.

Thank you for joining us today to discuss Aerohead's results for its fiscal 20253rd quarter ended June

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.